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Proceedings of the 2019 Canadian Inflammatory 
Myopathy Study Symposium: Clinical Trial Readiness 
in Myositis
Valérie Leclair, Océane Landon-Cardinal, Rohit Aggarwal, Nick Bansback, Craig Campbell, 
Brian M. Feldman, Martin Jarry, Suzan McNamara, Barbara White, and Marie Hudson,  
for the CIMS Investigators 
ABSTRACT. The Canadian Inflammatory Myopathy Study (CIMS) is a multicenter prospective cohort recruiting 
in 8 centers across Canada. One of the aims of CIMS is to conduct and participate in clinical trials 
in autoimmune inflammatory myopathies (AIM). Conducting clinical trials in rare diseases such as 
AIM presents challenges. During this symposium, experts in the field presented different solutions to 
successfully conduct clinical trials in AIM, including the importance of collaboration and careful trial 
design, as well as training and mentoring of young investigators. (J Rheumatol First Release June 15 
2020; doi:10.3899/jrheum.200480)
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The Canadian Inflammatory Myopathy Study (CIMS) 
group held its second national symposium in Montreal, 
Canada, on December 6, 2019. The goal was to develop 
capacity to conduct and participate in clinical trials 
in autoimmune inflammatory myopathies (AIM). The 
meeting was organized by Drs. Marie Hudson (chair), 
Océane Landon-Cardinal, and Valérie Leclair. The 
event was attended by 11 rheumatologists, 1 neurolo-
gist, 1 pediatric rheumatologist, 1 pediatric neurologist, 
1 neuropathologist, 1 respirologist, 1 physiotherapist, 1 
nurse clinician, 2 patient research partners, 2 non-medical 
scientists, and 3 representatives of the pharmaceutical 
industry. The symposium was sponsored by a Canadian 
Initiative for Outcomes in Rheumatology cAre (CIORA) 
grant, the McGill Interdisciplinary Initiative in Infection 
and Immunity (MI4), and industry.
 The CIMS cohort was inspired by a strong Canadian 
commitment to collaborative research in rheumatic diseases. 
It was created and enrolled its first subjects in 2014. This 
pan-Canadian multicentered prospective cohort has now 
recruited more than 230 AIM subjects from 8 sites across 
Canada. Data are collected annually and entered into a 
central database for the purpose of epidemiological and 
discovery research1,2,3,4,5. The next goal for the study group 
 www.jrheum.orgDownloaded on June 16, 2021 from 
2 The Journal of Rheumatology 2020; 47:doi:10.3899/jrheum.200480
 
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2020. All rights reserved. Personal non-commercial use only. The Journal of Rheumatology Copyright © 2020. All rights reserved.
is to develop capacity to conduct and participate in clinical 
trials in AIM. 
 Martin Jarry and Suzan McNamara, 2 patient advocates, 
opened the symposium. They emphasized the importance of 
patient advocacy in rare diseases and how this could shape 
the research agenda, even that of industry6. With an overall 
incidence of 8–18 cases/million/year and a prevalence of 
14–30 cases/100,000, AIM is a rare disease7. At the moment, 
most industry-sponsored clinical trials in adult AIM do not 
include Canadian sites. Canadian patients with AIM are 
thus at a considerable disadvantage regarding early access 
to potentially novel therapeutic interventions. Yet Canada 
has strengths that could help attract industry, including a 
favorable exchange rate. The challenges of conducting clin-
ical trials in Canada and possible solutions were examined 
throughout the symposium and are summarized in Table 1.
 Collaboration facilitates translational research and accel-
erates access to clinical trials for patients with neuromus-
cular diseases. TREAT-NMD is an example of a global 
network in neuromuscular diseases offering an infrastruc-
ture to connect researchers, clinicians, patients, and industry 
worldwide8. The chair of the TREAT-NMD Global patient 
registry, Dr. Craig Campbell, outlined its multifaceted 
approach to clinical trials facilitation including training and 
education as well as guidance for study planning. The global 
registry also serves as a link to easily locate centers that 
could be sites for any given trial, benefiting both patients 
and industry. A key message from this session was that it is 
important for research groups to identify common goals and 
to build their network infrastructure around them, because a 
desire to cover too much ground can lead to failure. 
 Dr. Brian Feldman, a pediatric rheumatologist and clini-
cian-researcher, shared his experience conducting clinical 
trials in AIM. The pediatric rheumatology community has 
been a leader in successful collaborative networks such as the 
Childhood Arthritis and Rheumatology Research Alliance 
(CARRA) and the Pediatric Rheumatology International 
Trials Organisation (PRINTO) and has played a major 
role in the International Myositis Assessment and Clinical 
Study group. Those groups were key in developing outcome 
measures and standardizing treatments in juvenile derma-
tomyositis9,10,11. One of the main points of Dr. Feldman’s 
presentation was the benefit of “thinking outside the box” 
when designing clinical trials in AIM. He presented alterna-
tive study designs and analytic methods such as pragmatic 
trials and the inverse probability of treatment weighting 
of observational data that are cost-effective and leverage 
existing research infrastructure12,13. 
 Dr. Rohit Aggarwal, an adult rheumatologist and 
clinician researcher, discussed trial design and outcome 
measures in AIM. He presented the strengths and limitations 
of the 2016 American College of Rheumatology/European 
League Against Rheumatism criteria for clinical response in 
dermatomyositis and polymyositis14. Notably, he discussed 
the pitfalls of the core set measures including the manual 
muscle testing (operator dependent, ceiling effect) and global 
activity visual analog scales (subjective, assessing several 
constructs at once). Dr. Aggarwal discussed newer outcome 
measures that could be easier to implement in a busy clin-
ical practice such as physical activity monitors, physical 
function testing (e.g., Sit-to-Stand, 6-minute walk test, and 
timed up and go) as well as devices to obtain more objec-
tive measures of muscle strength, such as handheld dyna-
mometers)15,16. Dr. Aggarwal proposed the idea of a Myositis 
Clinical Trial Consortium that would have as a primary goal 
facilitating multicentered clinical trials in AIM. In a similar 
manner as TREAT-NMD, this consortium would facilitate 
planning and collaboration between different centers and 
would support clinical trial readiness by mentoring junior 
investigators, sharing standard operating procedure, and 
developing classification criteria/outcome measures. 
 Dr. Nick Bansback, a health economist, described 
emerging methods to co-design trials in collaboration with 
patients. The need for alternatives to traditional trial design 
has emerged from the increasing recognition that a lot of 
resources are invested in trials investigating treatments that 
many patients do not want, either through the treatment 
characteristics (mode of delivery, side-effect profile) or trial 
outcomes that are not sufficient to guide a patient’s treatment 
decisions. In AIM, where patients and resources are scarce, 
patient-centered approaches could ensure optimal manage-
ment of resources. While patient-reported outcomes are 
important and of interest for regulatory agencies, they do not 
always reflect patient preferences or priorities. Dr. Bansback 
explained the basis of patient-centered trial designs using 
examples from studies in rheumatoid arthritis and systemic 
sclerosis17,18.
 Finally, Dr. Barbara White, chief medical officer for 
Corbus Pharmaceuticals, gave an industry perspective on 
conducting clinical trials in rare diseases. Dr. White acknowl-
edged the need for new treatments in AIM, but pointed out 
that the rarity of the disease, the lack of consensus on classi-
fication criteria, and the complexity of the outcome measures 
Table 1. Challenges of conducting autoimmune inflammatory myopathies 
(AIM) clinical trials in Canada.
Challenge Possible Solution
Limited resources Consider innovative trial designs (e.g.,   
 pragmatic trials, patient-centered outcomes).  
 Facilitate recruitment using established AIM  
 registries.
Regulatory agencies Partner with regulators to develop and validate  
 outcome measures that meet their requirements.
Inexperienced   Mentor young investigators to increase capacity. 
investigators Create and maintain easily accessible training  
 resources.
Complex outcome  Develop and validate AIM subset-driven 
measures outcome measures that can be easily interpreted.
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were major challenges for industry sponsors as well as 
regulators. Dr. White emphasized that well-trained and 
committed site investigators and research personnel were 
key to raising industry interest and conducting successful 
trials. The importance for the AIM community to develop 
valid outcome measures that are meaningful to the patient 
and regulatory agencies was also discussed. 
 Some main points should be considered to achieve 
clinical trial readiness in AIM. First, collaboration was 
mentioned throughout the presentations and the speakers 
gave several examples of successful networks facilitating 
clinical trials in rare diseases. Second, planning and trial 
design, both traditional and innovative, were mentioned 
as crucial for successful clinical trials. Third, training and 
mentoring young investigators to provide them with the 
tools to meet sponsors’ expectations and encourage them to 
invest in research were deemed to be essential. 
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